This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Ethyl piperidinoacetylaminobenzoate is a medication indicated for the symptomatic treatment of acute and chronic gastritis.
- Generic Name
- Ethyl piperidinoacetylaminobenzoate
- DrugBank Accession Number
- DB16527
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Ethyl piperidinoacetylaminobenzoate (DB16527)
- Weight
- Average: 290.363
Monoisotopic: 290.163042576 - Chemical Formula
- C16H22N2O3
- Synonyms
- EPAB
- Ethyl p-(piperidinoacetylamino)benzoate
- Ethyl piperidinoacetylaminobenzoate
- Sulcain
- Sulcaine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Abdominal pain •••••••••••• •••••• Treatment of Burning sensation of the esophagus •••••••••••• •••••• Treatment of Burning sensation of the stomach •••••••••••• •••••• Treatment of Gastritis acute •••••••••••• •••••• Treatment of Gastritis chronic •••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ยาเม็ด ซัลเคน Ethyl piperidinoacetylaminobenzoate (100 MG) + Magaldrate (100 MG) Tablet บริษัท เคนยากุ (ประเทศไทย) จำกัด 1986-12-22 Not applicable Thailand 
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6M452G7O1F
- CAS number
- 41653-21-8
- InChI Key
- QLGIFPJNYPWBMQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H22N2O3/c1-2-21-16(20)13-6-8-14(9-7-13)17-15(19)12-18-10-4-3-5-11-18/h6-9H,2-5,10-12H2,1H3,(H,17,19)
- IUPAC Name
- ethyl 4-[2-(piperidin-1-yl)acetamido]benzoate
- SMILES
- CCOC(=O)C1=CC=C(NC(=O)CN2CCCCC2)C=C1
References
- General References
- FDA Thailand: Sulcain (Ethyl piperidinoacetylaminobenzoate, Magaldrate) Oral Tablet [Link]
- External Links
- ChemSpider
- 3184
- ChEBI
- 31576
- ChEMBL
- CHEMBL2106245
- ZINC
- ZINC000000200489
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 2.31 Chemaxon pKa (Strongest Acidic) 12.81 Chemaxon pKa (Strongest Basic) 7.14 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 58.64 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 83.27 m3·mol-1 Chemaxon Polarizability 32.59 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0005-1090000000-2c653d00666dcf995e52 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-5b4d45d272fedd72f0e0 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-4690000000-96bcb88834b1e86a3929 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-4890000000-785bddec89226edb0ce2 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0f6t-7920000000-b6a1d81cc74612c48702 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-2900000000-f5682eeb5f65077f9b19 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 191.8610359 predictedDarkChem Lite v0.1.0 [M-H]- 172.1264 predictedDeepCCS 1.0 (2019) [M+H]+ 192.1965359 predictedDarkChem Lite v0.1.0 [M+H]+ 174.4844 predictedDeepCCS 1.0 (2019) [M+Na]+ 192.1001359 predictedDarkChem Lite v0.1.0 [M+Na]+ 180.57755 predictedDeepCCS 1.0 (2019)
Drug created at February 01, 2021 16:55 / Updated at May 05, 2021 20:32